These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. [Contribution of molecular genetics to the detection of carriers of severe genetic diseases]. Baiget Bastus M; Estivill Palleja X; Gallano Petit P; Nunes MartÃnez V An Esp Pediatr; 1989 Jul; 31(1):1-4. PubMed ID: 2802399 [No Abstract] [Full Text] [Related]
47. Variability among state Crippled Children's Service programs: pluralism thrives. Ireys HT; Hauck RJ; Perrin JM Am J Public Health; 1985 Apr; 75(4):375-81. PubMed ID: 3156516 [TBL] [Abstract][Full Text] [Related]
48. Human Genome Project and cystic fibrosis--a symbiotic relationship. Tolstoi LG; Smith CL J Am Diet Assoc; 1999 Nov; 99(11):1421-7. PubMed ID: 10570680 [TBL] [Abstract][Full Text] [Related]
49. Treatment of patients with severe combined immunodeficiency due to adenosine deaminase (ADA) deficiency by autologous transplantation of genetically modified bone marrow cells. Hoogerbrugge PM; Vossen JM; v Beusechem VW; Valerio D Hum Gene Ther; 1992 Oct; 3(5):553-8. PubMed ID: 1420454 [No Abstract] [Full Text] [Related]
50. [Gene therapy for hereditary and acquired human diseases]. Mehtali M; Imler JL; Sorg T; Pavirani A Ann Endocrinol (Paris); 1995; 56(6):571-4. PubMed ID: 8787346 [TBL] [Abstract][Full Text] [Related]
51. European Society of gene therapy-11th annual conference. Douglas JT IDrugs; 2004 Jan; 7(1):40-1. PubMed ID: 14968816 [No Abstract] [Full Text] [Related]
52. Good Laboratory Practice Preclinical Safety Studies for GSK2696273 (MLV Vector-Based Ex Vivo Gene Therapy for Adenosine Deaminase Deficiency Severe Combined Immunodeficiency) in NSG Mice. Carriglio N; Klapwijk J; Hernandez RJ; Vezzoli M; Chanut F; Lowe R; Draghici E; Nord M; Albertini P; Cristofori P; Richards J; Staton H; Appleby J; Aiuti A; Sauer AV Hum Gene Ther Clin Dev; 2017 Mar; 28(1):17-27. PubMed ID: 28319446 [TBL] [Abstract][Full Text] [Related]
53. Gene therapy: lessons learnt from the past decade. Interview by Clare Thompson. Morgan RA; Blaese RM BMJ; 1999 Nov; 319(7220):1310. PubMed ID: 10559061 [No Abstract] [Full Text] [Related]
54. Genetic manipulation of hematopoietic stem cells in adenosine deaminase deficiency. Williams DA; Moritz T Adv Exp Med Biol; 1994; 370():395-400. PubMed ID: 7660937 [No Abstract] [Full Text] [Related]
55. Successful Treatment With Ledipasvir/Sofosbuvir in an Infant With Severe Combined Immunodeficiency Caused by Adenosine Deaminase Deficiency With HCV Allowed Gene Therapy with Strimvelis. Tucci F; Calbi V; Barzaghi F; Migliavacca M; Ferrua F; Bernardo ME; Canarutto D; Consiglieri G; Recupero S; Calzatini F; Gabaldo M; Lucano C; Casiraghi M; Darin S; Dionisio F; Marktel S; Cestone E; Finazzi R; Mieli-Vergani G; Boeri E; Appleby J; Abd Elaziz D; Ciceri F; Aiuti A; Cicalese MP Hepatology; 2018 Dec; 68(6):2434-2437. PubMed ID: 30014500 [No Abstract] [Full Text] [Related]
57. Genomics as a probe for disease biology. Burke W N Engl J Med; 2003 Sep; 349(10):969-74. PubMed ID: 12954746 [No Abstract] [Full Text] [Related]
58. The current clinical revolution. Applications of gene therapy in treatment of disease. Worden M Physician Assist; 1994 May; 18(5):83-8. PubMed ID: 10134065 [TBL] [Abstract][Full Text] [Related]
59. Gene therapy for severe combined immunodeficiency caused by adenosine deaminase deficiency: improved retroviral vectors for clinical trials. Onodera M; Nelson DM; Sakiyama Y; Candotti F; Blaese RM Acta Haematol; 1999; 101(2):89-96. PubMed ID: 10202239 [TBL] [Abstract][Full Text] [Related]
60. [Possibilities and perspectives of genetic engineering in management of genetic diseases, neoplasms and AIDS]. Nowak J Pol Arch Med Wewn; 1993 May; 89(5):418-23. PubMed ID: 8367377 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]